Table 2.
The Reported COVID-19 Vaccine Side Effects and Their Correlation with the Vaccine’s First, Second, and Both Doses
| Frequency (n and %) | ||||
|---|---|---|---|---|
| 1st Dose (n = 237) | 2nd Dose (n = 124) | 1st & 2nd Doses (n=94) | Chi-Square p value | |
| Presence of Symptoms | ||||
| Presence | 202 (85.2%) | 122 (98.4%) | 68 (72.3%) | < 0.0001*** |
| Absence | 35 (14.8%) | 2 (1.6%) | 26 (27.7%) | |
| Local Symptoms | 167 (70.5%) | 100 (80.6%) | 60 (63.8%) | 0.0139* |
| Arm pain | 4 (1.7%) | 0 (0%) | 0 (0%) | 0.1563 |
| Injection site pain | 161 (67.9%) | 100 (80.6%) | 60 (63.8%) | 0.0116* |
| Injection site swelling and redness | 2 (0.8%) | 0 (0%) | 0 (0%) | 0.3907 |
| Hypersensitivity Symptoms | 19 (8.0%) | 18 (14.5%) | 3 (3.2%) | 0.0099** |
| A fast heartbeat | 7 (3.0%) | 11 (8.9%) | 3 (3.2%) | 0.0299* |
| Difficulty breathing | 9 (3.8%) | 5 (4.0%) | 0 (0%) | 0.1514 |
| Bad rash all over the body | 0 (0%) | 1 (0.8%) | 0 (0%) | 0.2625 |
| Severe body allergy | 1 (0.4%) | 0 (0%) | 0 (0%) | 0.6307 |
| Burning sensation in the eye | 2 (0.8%) | 1 (0.8%) | 0 (0%) | 0.6743 |
| Bone and Muscle Symptoms | 9 (3.8%) | 22 (17.7%) | 7 (7.4%) | < 0.0001*** |
| Whole body pain | 2 (0.8%) | 8 (6.5%) | 5 (5.3%) | 0.0084** |
| Muscle pain | 2 (0.8%) | 1 (0.8%) | 1 (1.1%) | 0.9764 |
| Muscle relaxation | 0 (0%) | 1 (0.8%) | 0 (0%) | 0.2625 |
| Bone pain | 3 (1.3%) | 2 (1.6%) | 0 (0%) | 0.4949 |
| Joint pain | 0 (0.0%) | 5 (4.0%) | 1 (1.1%) | 0.0060** |
| Back pain | 2 (0.8%) | 3 (2.4%) | 0 (0%) | 0.2044 |
| Total Flu-Like Symptoms | 77 (32.5%) | 112 (90.3%) | 29 (30.9%) | < 0.0001*** |
| Flu symptoms | 26 (11.0%) | 36 (29.0%) | 7 (7.4%) | < 0.0001*** |
| Headache | 43 (18.1%) | 48 (38.7%) | 17 (18.1%) | < 0.0001*** |
| Fever | 3 (1.3%) | 23 (18.5%) | 4 (4.3%) | < 0.0001*** |
| Chills | 2 (0.8%) | 5 (4.0%) | 1 (1.1%) | 0.0772 |
| Sore throat | 2 (0.8%) | 0 (0%) | 0 (0%) | 0.3907 |
| Chest infection | 1 (0.4%) | 0 (0%) | 0 (0%) | 0.6307 |
| Fatigue Symptoms | 20 (8.4%) | 25 (20.1%) | 3 (3.2%) | < 0.0001*** |
| Tiredness | 15 (6.3%) | 19 (15.3%) | 3 (3.2%) | 0.2171 |
| Dizziness and giddiness | 4 (1.7%) | 2 (1.6%) | 0 (0%) | 0.4523 |
| Desire to sleep | 1 (0.4%) | 4 (3.2%) | 0 (0%) | 0.0273* |
| GIT Symptoms | 14 (5.9%) | 2 (1.6%) | 1 (1.1%) | 0.0383* |
| Nausea and vomiting | 4 (1.7%) | 1 (0.8%) | 1 (1.1%) | 0.7615 |
| Gastroesophagitis | 2 (0.8%) | 0 (0%) | 0 (0%) | 0.3907 |
| Diarrhea | 7 (3.0%) | 1 (0.8%) | 0 (0%) | 0.1169 |
| Loss of appetite | 1 (0.4%) | 0 (0%) | 0 (0%) | 0.6307 |
| Nerve Inflammation Symptoms | 4 (1.7%) | 0 (0%) | 0 (0%) | 0.1563 |
| Bell’s palsy | 3 (1.3%) | 0 (0%) | 0 (0%) | 0.2493 |
| Tingling | 1 (0.4%) | 0 (0%) | 0 (0%) | 0.6307 |
| Miscellaneous Symptoms | 1 (0.4%) | 4 (3.2%) | 0 (0%) | 0.0273* |
| Lymph nodes tenderness and swelling | 0 (0%) | 2 (1.6%) | 0 (0%) | 0.0685 |
| Elevated blood pressure | 0 (0%) | 1 (0.8%) | 0 (0%) | 0.2625 |
| Blurred vision | 0 (0%) | 1 (0.8%) | 0 (0%) | 0.2625 |
| Burning sensation when urinating | 1 (0.4%) | 0 (0%) | 0 (0%) | 0.6307 |
Notes: Results were offered as frequency (number (n) and percent (%)). Correlation between variables was evaluated using the Chi-square test. *Significant difference at p ≤ 0.05, **significant difference at p ≤ 0.01, and ***significant difference at p ≤ 0.001.